On 13 September 2024, Regeneron and Sanofi announced that their Dupixent® (dupilumab) has received FDA approval as an add-on maintenance treatment for patients aged 12-17 with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). This follows the FDA’s May 2024 acceptance of the sBLA for Dupixent® for priority review for adolescents with CRSwNP.
On 25 July 2024, Sanofi revealed that its worldwide sales of Dupixent® grew by 29.2% to €3,303 million in the second quarter of 2024. Sanofi expects the product to generate revenue of about €13 billion for 2024.